Compare OVLY & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | OBIO |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4M | 240.7M |
| IPO Year | 2008 | 2020 |
| Metric | OVLY | OBIO |
|---|---|---|
| Price | $33.59 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 68.4K | ★ 222.8K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $52.61 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $25.25 | $2.20 |
| 52 Week High | $35.97 | $5.42 |
| Indicator | OVLY | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 47.11 |
| Support Level | $32.07 | $3.77 |
| Resistance Level | $33.82 | $4.18 |
| Average True Range (ATR) | 1.11 | 0.18 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 40.18 | 45.00 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.